Coronary stents: historical development, current status and future directions

Abstract

There are on-going preclinical and clinical studies to develop better stent platforms, more biocompatible polymers, novel anti-proliferative and anti-platelet drugs, pro-healing stents and bioresorbable scaffolds.

Mutual influence of incorporated drugs in a dual drug delivery coating for cardiovascular applications

“…During our screenings the highest VEGF loading was detected for BS 3 as crosslinker. Furthermore the immobilization is realized by hydrolytic cleavable ester bonds as it is known that surface immobilized VEGF enhance reendothelialization [10,15].…”

“…DES with Paclitaxel (PTX) as cytostatic drug reduce neointimal hyperplasia by inhibition of smooth muscle cell proliferation [2,3]. A side action is the arresting of the endothelial cell proliferation and growth resulting in increased risk of late instent thrombosis [4,5].…”

A modern generation of drug-eluting stents. Focusing on a sirolimus-eluting stent Calypso

“…Для наиболее полного анализа необходимо сфор-мулировать следующие основные требования, предъ-являемые к коронарным стентам [31][32][33] (табл. 1).…”

Role of Rotational Atherectomy in Percutaneous Coronary Interventions in Elderly

“…Though coronary angiography and angioplasty has evolved tremendously with introduction of different coronary stents [2,3], balloons and wire, RA continues to have an established role in treatment of complex coronary artery disease in the cardiac cath lab. It was initially introduced as an alternative to balloon angioplasty but has now become an adjunct procedure during coronary intervention, especially of heavily calcified or fibrotic lesions.…”